1620 Investment Advisors’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$716K Buy
2,820
+36
+1% +$8.39K 0.44% 60
2026
Q1
$681K Sell
2,784
-2
-0.1% -$466 0.46% 62
2025
Q4
$577K Buy
2,786
+4
+0.1% +$791 0.38% 79
2025
Q3
$516K Sell
2,782
-36
-1% -$6.17K 0.35% 84
2025
Q2
$431K Buy
2,818
+59
+2% +$9.07K 0.31% 96
2025
Q1
$457K Buy
2,759
+45
+2% +$7.04K 0.35% 88
2024
Q4
$392K Buy
2,714
+15
+0.6% +$2.32K 0.3% 103
2024
Q3
$437K Buy
2,699
+33
+1% +$5.26K 0.32% 95
2024
Q2
$390K Hold
2,666
0.3% 99
2024
Q1
$422K Sell
2,666
-30
-1% -$4.78K 0.42% 79
2023
Q4
$423K Sell
2,696
-4,362
-62% -$669K 0.46% 75
2023
Q3
$376K Buy
7,058
+4,413
+167% +$728K 0.43% 83
2023
Q2
$438K Buy
2,645
+5
+0.2% +$807 0.47% 74
2023
Q1
$409K Buy
2,640
+19
+0.7% +$3.07K 0.49% 70
2022
Q4
$463K Buy
2,621
+48
+2% +$8.29K 0.56% 63
2022
Q3
$420K Buy
2,573
+29
+1% +$4.91K 0.62% 59
2022
Q2
$452K Buy
2,544
+157
+7% +$28K 0.62% 58
2022
Q1
$408K Hold
2,387
0.44% 80
2021
Q4
$408K Buy
+2,387
New +$391K 0.46% 76

Other funds holding JNJ

1620 Investment Advisors's JNJ Position: Q2 2026 in Review

1620 Investment Advisors increased its Johnson & Johnson (JNJ) stake by 1.3% in Q2 2026, buying an estimated $8.39K and bringing the position to 2,820 shares worth $716K. The position accounts for 0.44% of the portfolio, ranked #60.

1620 Investment Advisors first reported a position in JNJ in Q4 2021 and has held it in 19 quarters since. 1,657 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • 1620 Investment Advisors held 2,820 shares of Johnson & Johnson worth $716K as of Q2 2026.
  • 1620 Investment Advisors bought 36 Johnson & Johnson shares in Q2 2026, an estimated $8.39K.
  • Johnson & Johnson made up 0.44% of 1620 Investment Advisors's portfolio in Q2 2026, its #60 holding.
  • 1620 Investment Advisors first reported a position in Johnson & Johnson in Q4 2021 and has held it in 19 quarters since.
  • 1,657 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.